Heterologous ET-743 Production via Gene Cluster Sequencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge lies in obtaining sufficient amounts of the chemotherapeutic natural product ET-743, as it is produced in low yields from natural sources and is difficult to culture the uncultivable bacterial symbiont Candidatus Endoecteinascidia frumentensis, hindering the study of its biosynthetic pathways and commercial production.
Innovation Solution
Next-generation sequencing technologies were used to identify and sequence the complete biosynthetic gene cluster of Candidatus Endoecteinascidia frumentensis, allowing for the development of methods to synthesize ET-743 or its analogs in host cells through expression vectors encoding specific polypeptides, enabling biochemical and heterologous expression experiments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If next-generation sequencing is used to identify and sequence the complete biosynthetic gene cluster, then the ability to study and produce ET-743 is improved, but the complexity of the research methodology increases
Solution Approach 1:
The patent creates copies of the biosynthetic gene cluster through sequencing and cloning into expression vectors. The complete gene cluster is copied from the uncultivable symbiont into cultivable host cells, allowing study and production without needing to culture the original organism. This copying approach preserves all biosynthetic information while enabling experimental manipulation.
Solution Approach 2:
The patent uses expression vectors and host cells as intermediaries between the uncultivable symbiont and the researcher. The gene cluster acts as an intermediary carrier of biosynthetic information, and host cells serve as intermediary factories for producing ET-743, bridging the gap between the inaccessible original producer and the research objectives.
2Productivity
If heterologous expression of biosynthetic genes is implemented in host cells, then ET-743 production capacity is improved, but the device and process complexity increases
Solution Approach 1:
The patent segments the complex biosynthetic pathway into individual gene clusters that can be independently cloned and expressed. The NRPS gene cluster is separated and inserted into expression vectors, allowing modular construction of the production system. This segmentation enables stepwise optimization and simplifies troubleshooting compared to attempting to express the entire pathway simultaneously.
Solution Approach 2:
The patent uses universal expression vectors and host cell systems that can express foreign biosynthetic genes from the uncultivable symbiont. The expression system is designed to be universally applicable, accepting DNA inserts from various sources and producing the desired metabolite in diverse host organisms, thereby simplifying the overall production approach.
3Reliability
If the uncultivable bacterial symbiont Candidatus Endoecteinascidia frumentensis is cultured, then direct study of biosynthetic pathways is improved, but the ease of operation deteriorates due to inability to culture
Solution Approach 1:
The patent extracts the biosynthetic gene cluster from the uncultivable symbiont and transfers it into cultivable host cells. By taking out the essential genetic information from the inaccessible original producer and placing it in tractable host systems, the patent enables reliable study and production without requiring culture of the symbiont itself. This extraction approach maintains biosynthetic fidelity while dramatically improving ease of operation.
Data Source
AI summary
The present disclosure is directed to the biosynthetic pathway for a nonribosomal peptide synthetase (NRPS)-derived drug and analogs thereof. The invention provides polynucleotide sequences useful for heterologous expression in a convenient microbial host for the synthesis of the NRPS-derived drug, the polypeptides encoded by such polynucleotides, expression vectors comprising the polynucleotides, host cells comprising the polynucleotides or expression vectors, and kits comprising a host cell. Also provided is a method for the production of ET-743, the NRPS-derived drug.